In the United States, oral and injectable forms of SMG are approved for treating T2DM, while only injectable forms are approved for treating obesity (103)
Beyond obesity, retatrutide is being investigated for type 2 diabetes and metabolic dysfunction-associated steatohepatitis (MASH), conditions where the combination of weight loss, improved glycemic control, and enhanced hepatic fat oxidation could provide comprehensive therapeutic benefits
aim for a 90-day window of daily use to truly evaluate the impact on your metabolic health
Surprisingly, a growing number of clinical studies demonstrate that these drugs (and other GLP-1 RAs) may have benefits that extend far beyond their original purpose, with their effects spanning the heart, kidneys, liver, and more
How Long-Term Metabolic Health Should Be Measured The best maintenance plans measure more than body weight
What concentration should I use for these IU values